Mariano Barbacid

List of Publications by Year
in descending order

148 papers	41,631 citations	5574 82 h-index	8630 146 g-index
149 all docs	149 docs citations	149 times ranked	36296 citing authors

#	Article	IF	Citations
1	Targeting KRAS mutant lung cancer: light at the end of the tunnel. Molecular Oncology, 2022, 16, 1057-1071.	4.6	23
2	KSR induces RASâ€independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Molecular Oncology, 2022, 16, 3066-3081.	4.6	10
3	Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor. Cancers, 2022, 14, 3102.	3.7	4
4	Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells. Cancer Research, 2021, 81, 2679-2689.	0.9	11
5	RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. Cancer Cell, 2021, 39, 294-296.	16.8	18
6	KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
7	Definitive evidence for Club cells as progenitors for mutant Kras/Trp53â€deficient lung cancer. International Journal of Cancer, 2021, 149, 1670-1682.	5.1	5
8	TARGETING KRAS SIGNALING IN PANCREATIC CANCER.. Pancreatology, 2020, 20, e18.	1.1	0
9	Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24415-24426.	7.1	15
10	Requirement for epithelial p38Î± in KRAS-driven lung tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2588-2596.	7.1	16
11	Targeting the MAPK Pathway in KRAS-Driven Tumors. Cancer Cell, 2020, 37, 543-550.	16.8	253
12	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell, 2019, 35, 573-587.e6.	16.8	75
13	RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature Medicine, 2019, 25, 284-291.	30.7	125
14	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery, 2018, 8, 648-661.	9.4	97
15	ERF deletion rescues RAS deficiency in mouse embryonic stem cells. Genes and Development, 2018, 32, 568-576.	5.9	13
16	c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell, 2018, 33, 217-228.e4.	16.8	93
17	Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1147-E1156.	7.1	128
18	The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle, 2018, 17, 702-711.	2.6	36

#	Article	IF	Citations
19	Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031542.	6.2	19
20	Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9282-9287.	7.1	68
21	Afatinib restrains K-RASâ€"driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	12.4	99
22	Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions. Oncologist, 2017, 22, 335-342.	3.7	39
23	Cyclin-Dependent Kinase 4 Regulates Adult Neural Stem Cell Proliferation and Differentiation in Response to Insulin. Stem Cells, 2017, 35, 2403-2416.	3.2	29
24	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes and Development, 2017, 31, 1456-1468.	5.9	41
25	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 2017, 548, 234-238.	27.8	394
26	A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature, 2017, 548, 239-243.	27.8	85
27	Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies. Biological Psychiatry, 2017, 81, 179-192.	1.3	30
28	H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences. Cancer Research, 2017, 77, 707-718.	0.9	21
29	A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genetics, 2017, 13, e1006622.	3.5	45
30	KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. ESMO Open, 2016, 1, e000076.	4.5	19
31	The European Cancer Patientâ€™s Bill of Rights, update and implementation 2016. ESMO Open, 2016, 1, e000127.	4.5	36
32	Ras and p53: An unsuspected liaison. Molecular and Cellular Oncology, 2016, 3, e996001.	0.7	2
33	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nature Medicine, 2016, 22, 270-277.	30.7	150
34	Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets. Journal of Molecular Medicine, 2016, 94, 121-135.	3.9	12
35	H-Ras Distribution and Signaling in Plasma Membrane Microdomains Are Regulated by Acylation and Deacylation Events. Molecular and Cellular Biology, 2015, 35, 1898-1914.	2.3	30
36	Functional Reprogramming of Polyploidization in Megakaryocytes. Developmental Cell, 2015, 32, 155-167.	7.0	47

#	Article	IF	Citations
37	Therapeutic inhibition of <scp>TRF</scp> 1 impairs the growth of p53 â€deficient Kâ€Ras ^{G12V} â€ induced lung cancer by induction of telomeric <scp>DNA</scp> damage. EMBO Molecular Medicine, 2015, 7, 930-949.	6.9	45
38	Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 255-260.	7.1	151
39	A Catalyst for Change: The European Cancer Patient's Bill of Rights. Oncologist, 2014, 19, 217-224.	3.7	35
40	K-Ras ^{V14I} recapitulates Noonan syndrome in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16395-16400.	7.1	67
41	Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. Cancer Research, 2014, 74, 5978-5988.	0.9	30
42	Genetic Characterization of the Role of the Cip/Kip Family of Proteins as Cyclin-Dependent Kinase Inhibitors and Assembly Factors. Molecular and Cellular Biology, 2014, 34, 1452-1459.	2.3	28
43	Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology, 2014, 59, 651-660.	7.3	41
44	Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15155-15160.	7.1	80
45	Ras in epidermal proliferation. Oncotarget, 2014, 5, 5194-5195.	1.8	0
46	Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 232-247.	4.6	140
47	Mouse models of cancer. Molecular Oncology, 2013, 7, 143-145.	4.6	14
48	Genetic analysis of Ras genes in epidermal development and tumorigenesis. Small GTPases, 2013, 4, 236-241.	1.6	8
49	Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas. PLoS ONE, 2013, 8, e66933.	2.5	11
50	Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO Journal, 2012, 31, 2498-2510.	7.8	85
51	EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 22, 318-330.	16.8	339
52	Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5208-5214.	2.2	19
53	Opening a New GATAway for Treating KRAS-Driven Lung Tumors. Cancer Cell, 2012, 21, 598-600.	16.8	8
54	Identification of ETP-46321, a potent and orally bioavailable PI3K Î±, Î´ inhibitor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3460-3466.	2.2	24

#	Article	IF	Citations
55	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nature Structural and Molecular Biology, 2011, 18, 1331-1335.	8.2	342
56	A Pericyte Origin of Spinal Cord Scar Tissue. Science, 2011, 333, 238-242.	12.6	711
57	Mutant K-Ras Activation of the Proapoptotic MST2 Pathway Is Antagonized by Wild-Type K-Ras. Molecular Cell, 2011, 44, 893-906.	9.7	127
58	c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma. Cancer Cell, 2011, 19, 652-663.	16.8	260
59	Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence. Cancer Cell, 2011, 19, 728-739.	16.8	437
60	Cdk6-Dependent Regulation of G1 Length Controls Adult Neurogenesis. Stem Cells, 2011, 29, 713-724.	3.2	54
61	Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5015-5020.	7.1	61
62	Toll-like Receptor-4 (TLR4) Down-regulates MicroRNA-107, Increasing Macrophage Adhesion via Cyclin-dependent Kinase 6. Journal of Biological Chemistry, 2011, 286, 25531-25539.	3.4	56
63	A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma. Cancer Cell, 2010, 18, 63-73.	16.8	373
64	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nature Structural and Molecular Biology, 2010, 17, 718-725.	8.2	141
65	Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO Journal, 2010, 29, 1091-1104.	7.8	267
66	Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nature Cell Biology, 2010, 12, 54-59.	10.3	218
67	Overall Cdk activity modulates the DNA damage response in mammalian cells. Journal of Cell Biology, 2009, 187, 773-780.	5.2	53
68	Cell cycle, CDKs and cancer: a changing paradigm. Nature Reviews Cancer, 2009, 9, 153-166.	28.4	3,070
69	Postnatal Schwann cell proliferation but not myelination is strictly and uniquely dependent on cyclin-dependent kinase 4 (cdk4). Molecular and Cellular Neurosciences, 2008, 37, 519-527.	2.2	26
70	CDK inhibitors in cancer therapy: what is next?. Trends in Pharmacological Sciences, 2008, 29, 16-21.	8.7	234
71	A mouse model for Costello syndrome reveals an Ang IIâ€"mediated hypertensive condition. Journal of Clinical Investigation, 2008, 118, 2169-79.	8.2	97
72	Returning Home. Cell, 2007, 129, 641-644.	28.9	1

#	Article	IF	Citations
73	Cell cycle kinases in cancer. Current Opinion in Genetics and Development, 2007, 17, 60-65.	3.3	300
74	Mice thrive without Cdk4 and Cdk2. Molecular Oncology, 2007, 1, 72-83.	4.6	99
75	p38Î± MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nature Genetics, 2007, 39, 750-758.	21.4	278
76	Cdk1 is sufficient to drive the mammalian cell cycle. Nature, 2007, 448, 811-815.	27.8	888
77	Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice. Cancer Cell, 2007, 11, 291-302.	16.8	1,042
78	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. American Journal of Pathology, 2006, 169, 665-672.	3.8	53
79	Is Cyclin D1-CDK4 kinase a bona fide cancer target?. Cancer Cell, 2006, 9, 2-4.	16.8	96
80	Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. International Journal of Cancer, 2006, 118, 373-380.	5.1	12
81	Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14122-14127.	7.1	181
82	Spontaneous and UV Radiationâ€"Induced Multiple Metastatic Melanomas in Cdk4R24C/R24C/TPras Mice. Cancer Research, 2006, 66, 2946-2952.	0.9	52
83	Senescence in premalignant tumours. Nature, 2005, 436, 642-642.	27.8	1,280
84	Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell, 2005, 7, 313-324.	16.8	106
85	Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. Cancer Cell, 2005, 7, 591-598.	16.8	205
86	Mammalian cyclin-dependent kinases. Trends in Biochemical Sciences, 2005, 30, 630-641.	7.5	1,069
87	Cooperation between Cdk4 and p27kip1 in Tumor Development: A Preclinical Model to Evaluate Cell Cycle Inhibitors with Therapeutic Activity. Cancer Research, 2005, 65, 3846-3852.	0.9	55
88	Cdk4 promotes adipogenesis through PPARÎ³ activation. Cell Metabolism, 2005, 2, 239-249.	16.2	136
89	The European dimension for the mouse genome mutagenesis program. Nature Genetics, 2004, 36, 925-927.	21.4	195
90	Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6. Cell, 2004, 118, 493-504.	28.9	719

#	Article	IF	Citations
91	Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell, 2003, 4, 111-120.	16.8	518
92	Genetic rescue of Cdk4 null mice restores pancreatic Î²-cell proliferation but not homeostatic cell number. Oncogene, 2003, 22, 5261-5269.	5.9	118
93	Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nature Genetics, 2003, 35, 25-31.	21.4	802
94	RAS oncogenes: the first 30 years. Nature Reviews Cancer, 2003, 3, 459-465.	28.4	1,597
95	Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nature Immunology, 2001, 2, 548-555.	14.5	156
96	To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer, 2001, 1, 222-231.	28.4	1,289
97	Control of Spermatogenesis in Mice by the Cyclin D-Dependent Kinase Inhibitors p18 Ink4c and p19 Ink4d. Molecular and Cellular Biology, 2001, 21, 3244-3255.	2.3	103
98	Genetic Analysis of Ephrin-A2 and Ephrin-A5 Shows Their Requirement in Multiple Aspects of Retinocollicular Mapping. Neuron, 2000, 25, 563-574.	8.1	450
99	Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in Î²-islet cell hyperplasia. Nature Genetics, 1999, 22, 44-52.	21.4	711
100	Nerve Dependency of Developing and Mature Sensory Receptor Cellsa. Annals of the New York Academy of Sciences, 1998, 855, 14-27.	3.8	20
101	Corneal innervation and sensitivity to noxious stimuli intrkA knockout mice. European Journal of Neuroscience, 1998, 10, 146-152.	2.6	82
102	Ephrin-A5 (AL-1/RAGS) Is Essential for Proper Retinal Axon Guidance and Topographic Mapping in the Mammalian Visual System. Neuron, 1998, 20, 235-243.	8.1	428
103	Topographic Guidance Labels in a Sensory Projection to the Forebrain. Neuron, 1998, 21, 1303-1313.	8.1	255
104	The combined effects of trkB and trkC mutations on the innervation of the inner ear. International Journal of Developmental Neuroscience, 1998, 16, 493-505.	1.6	59
105	TrkB and TrkC Signaling Are Required for Maturation and Synaptogenesis of Hippocampal Connections. Journal of Neuroscience, 1998, 18, 7336-7350.	3.6	230
106	A Role for TrkA during Maturation of Striatal and Basal Forebrain Cholinergic NeuronsIn Vivo. Journal of Neuroscience, 1997, 17, 7644-7654.	3.6	133
107	TrkB Signaling Is Required for Postnatal Survival of CNS Neurons and Protects Hippocampal and Motor Neurons from Axotomy-Induced Cell Death. Journal of Neuroscience, 1997, 17, 3623-3633.	3.6	182
108	Severe Sensory Deficits but Normal CNS Development in Newborn Mice Lacking TrkB and TrkC Tyrosine Protein Kinase Receptors. European Journal of Neuroscience, 1997, 9, 2045-2056.	2.6	124

#	Article	IF	Citations
109	A giant protein that stimulates guanine nucleotide exchange on ARF1 and Rab proteins forms a cytosolic ternary complex with clathrin and Hsp70. Oncogene, 1997, 15, 1-6.	5.9	61
110	Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated c-Jun N-terminal kinase activation. Oncogene, 1997, 15, 2511-2520.	5.9	87
111	Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system. Cell and Tissue Research, 1997, 290, 209-215.	2.9	17
112	Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular andin VivoActivity. Journal of Medicinal Chemistry, 1996, 39, 224-236.	6.4	82
113	Synchronous Onset of NGF and TrkA Survival Dependence in Developing Dorsal Root Ganglia. Journal of Neuroscience, 1996, 16, 4662-4672.	3.6	154
114	TrkA, But Not TrkC, Receptors Are Essential for Survival of Sympathetic NeuronsIn Vivo. Journal of Neuroscience, 1996, 16, 6208-6218.	3.6	180
115	Mice Lacking Brain-Derived Neurotrophic Factor Exhibit Visceral Sensory Neuron Losses Distinct from Mice Lacking NT4 and Display a Severe Developmental Deficit in Control of Breathing. Journal of Neuroscience, 1996, 16, 5361-5371.	3.6	342
116	Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature, 1996, 382, 70-73.	27.8	1,154
117	Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Development Research, 1995, 34, 121-137.	2.9	68
118	Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+CDS+thymocytes. Nature, 1995, 374, 474-476.	27.8	299
119	Phosphinyl Acid-Based Bisubstrate Analog Inhibitors of Farnesyl Protein Transferase. Journal of Medicinal Chemistry, 1995, 38, 435-442.	6.4	79
120	Neurotrophic factors and their receptors. Current Opinion in Cell Biology, 1995, 7, 148-155.	5.4	539
121	Structural and Functional Properties of the TRK Family of Neurotrophin Receptors. Annals of the New York Academy of Sciences, 1995, 766, 442-458.	3.8	240
122	The Trk family of neurotrophin receptors. Journal of Neurobiology, 1994, 25, 1386-1403.	3.6	1,187
123	Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature, 1994, 368, 246-249.	27.8	932
124	Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature, 1994, 368, 249-251.	27.8	607
125	High-affinity nerve growth factor receptor (Trk) immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. Brain Research, 1993, 612, 330-335.	2.2	153
126	Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron, 1993, 10, 137-149.	8.1	524

#	Article	IF	Citations
127	Nerve growth factor mediates signal transduction through trk homodimer receptors. Neuron, 1992, 9, 1067-1079.	8.1	452
128	The trk B tyrosine protein kinase is a receptor for neurotrophin-4. Neuron, 1992, 8, 947-956.	8.1	306
129	Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature, 1992, 356, 68-71.	27.8	320
130	The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell, 1991, 66, 173-183.	28.9	521
131	The trk proto-oncogene encodes a receptor for nerve growth factor. Cell, 1991, 65, 189-197.	28.9	1,368
132	trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell, 1991, 66, 967-979.	28.9	1,040
133	The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell, 1991, 66, 395-403.	28.9	881
134	The human VAV proto-oncogene maps to chromosome region 19p12?19p13.2. Human Genetics, 1990, 86, 65-8.	3.8	21
135	The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain. Cell, 1990, 61, 647-656.	28.9	712
136	A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature, 1986, 319, 743-748.	27.8	755
137	Mutagens, oncogenes and cancer. Trends in Genetics, 1986, 2, 188-192.	6.7	84
138	Oncogenes and human cancer: cause or consequence?. Carcinogenesis, 1986, 7, 1037-1042.	2.8	136
139	Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature, 1985, 315, 382-385.	27.8	872
140	Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature, 1983, 306, 658-661.	27.8	736
141	Transforming genes in human tumors. Journal of Cellular Biochemistry, 1982, 20, 51-61.	2.6	63
142	T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature, 1982, 298, 343-347.	27.8	616
143	A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature, 1982, 300, 149-152.	27.8	1,369
144	Oncogenes in solid human tumours. Nature, 1982, 300, 539-542.	27.8	480

#	Article	IF	Citations
145	Localization of the normal allele of T24 human bladder carcinoma oncogene to chromosome 11. Nature, 1982, 300, 773-774.	27.8	105
146	Evolutionary relationships between gag gene-coded proteins of murine and primate endogenous type C RNA viruses. Cell, 1977, 10, 641-648.	28.9	66
147	Differential Synthesis of Mammalian Type C Viral Gene Products in Infected Cells. Journal of Virology, 1977, 24, 1-7.	3.4	8
148	gag Gene of mammalian type-C RNA tumour viruses. Nature, 1976, 262, 554-559.	27.8	242